ADVFN US – Market Content Editor
-

Performance Food Group Shares Slip Despite Beating Q1 Expectations
Performance Food Group Company (NYSE:PFGC) posted better-than-expected fiscal first-quarter 2026 results on Wednesday, delivering double-digit revenue growth and higher profitability — yet its shares slipped 2.07% in premarket trading as investors focused on higher expenses and lower net income. The foodservice distribution company reported adjusted earnings of $1.18 per share, topping the consensus estimate of…
-

Frontdoor Tops Q3 Estimates, Lifts Full-Year Forecast on Strong Growth
Frontdoor, Inc. (NASDAQ:FTDR) — the leading U.S. provider of home warranties — beat Wall Street expectations for the third quarter, posting robust revenue and earnings growth that prompted the company to raise its full-year guidance. Revenue climbed 14% year-over-year to $618 million, surpassing the $608.14 million consensus estimate, while adjusted earnings per share came in…
-

SolarEdge Shares Sink as Weak Q4 Outlook Overshadows Strong Q3 Results
SolarEdge Technologies, Inc. (NASDAQ:SEDG) shares slid 10.4% on Wednesday after the company’s fourth-quarter revenue forecast fell short of analyst expectations, eclipsing a solid performance in the prior quarter. For the third quarter, the smart energy solutions provider reported an adjusted loss of $0.31 per share, beating the consensus estimate of a $0.41 loss. Revenue rose…
-

ScottsMiracle-Gro Beats Q4 Expectations, Lifts Outlook for 2026
ScottsMiracle-Gro Co. (NYSE:SMG) reported better-than-expected fourth-quarter results on Wednesday, as improved profitability offset slightly weaker revenue. Shares rose after the company issued an upbeat forecast for fiscal 2026, signaling confidence in continued margin and earnings growth. The lawn and garden products company posted an adjusted loss of $1.96 per share, topping analyst expectations by a…
-

Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook
Charles River Laboratories International, Inc. (NYSE:CRL) posted third-quarter results that beat analyst expectations, signaling stabilization across its early-stage drug development operations despite persistent headwinds in the broader healthcare sector. The company reported adjusted earnings of $2.43 per share, exceeding the $2.34 consensus estimate, while revenue came in at $1.0 billion, just above forecasts of $987.43…
-

First Majestic Silver Shares Slip After Q3 Earnings Miss Despite Record Revenue
First Majestic Silver Corp. (NYSE:AG) shares fell 2.7% on Wednesday after the precious metals producer reported third-quarter earnings that missed Wall Street forecasts, even as it delivered record revenue and output. The miner posted adjusted earnings of $0.07 per share, below the analyst consensus of $0.11 per share. Revenue rose 95% year-over-year to a record…
-

McDonald’s Q3 Sales Edge Past Expectations as Value Deals Drive Growth
McDonald’s Corp. (NYSE:MCD) reported third-quarter results showing global comparable sales up 3.6%, just above the 3.59% forecast from Bloomberg consensus, as cost-conscious consumers continued to flock to the chain’s value-driven offerings during a period of economic uncertainty. In the U.S., comparable sales climbed 2.4%, ahead of the 2.14% estimate and up sharply from 0.3% in…
-

Shutterstock Shares Gain 2% After Beating Q3 Earnings and Revenue Estimates
Shutterstock, Inc. (NYSE:SSTK) shares climbed 2.12% in premarket trading Wednesday after the visual content and creative platform reported third-quarter results that topped analyst expectations, led by continued strength in its Data, Distribution, and Services segment. The company posted adjusted earnings of $0.99 per share, far above consensus forecasts of $0.63, while revenue rose 4% year-over-year…
-

Sabre Shares Drop 7% After Q3 Profit Miss Despite Revenue Growth
Sabre Corp. (NASDAQ:SABR) shares fell 7% in premarket trading Wednesday after the travel technology company reported third-quarter 2025 earnings that missed Wall Street estimates, even as revenue edged higher year over year. The company posted an adjusted loss of $0.01 per share, below analyst expectations for a $0.04 profit. Revenue rose 3% year-over-year to $715.2…
-

NuCana Shares Climb After Securing Key Chinese Patent for Cancer Drug NUC-7738
NuCana plc (NASDAQ:NCNA) shares rose 8.9% in premarket trading Wednesday after the biopharmaceutical company announced it had been granted a major patent in China covering its experimental cancer treatment NUC-7738. The China National Intellectual Property Administration (CNIPA) issued the composition of matter patent (ZL 202010794701.2) for NUC-7738, which is currently in a Phase 1/2 clinical…